Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avalyn Pharma Inc. before investing.

In this article, we go over a few key elements for understanding Avalyn Pharma Inc.’s stock price such as:

• Avalyn Pharma Inc.’s current stock price and volume
• Why Avalyn Pharma Inc.’s stock price changed recently
• Upgrades and downgrades for AVLN from analysts
• AVLN’s stock price momentum as measured by its relative strength

About Avalyn Pharma Inc. (AVLN)

Before we jump into Avalyn Pharma Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Want to learn more about Avalyn Pharma Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avalyn Pharma Inc..

Avalyn Pharma Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Avalyn Pharma Inc.’s stock price was $37.390.

Avalyn Pharma Inc. is up 5.5% from its previous closing price of $35.440.

During the last market session, Avalyn Pharma Inc.’s stock traded between $34.900 and $38.340. Currently, there are approximately 29.65 million shares outstanding for Avalyn Pharma Inc..

Avalyn Pharma Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Avalyn Pharma Inc. Stock Price History

Avalyn Pharma Inc.’s (AVLN) price is currently up 7.66% so far this month.

During the month of September, Avalyn Pharma Inc.’s stock price has reached a high of $38.340 and a low of $34.310.

Over the last year, Avalyn Pharma Inc. has hit prices as high as $40.170 and as low as $24.150.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Avalyn Pharma Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded Avalyn Pharma Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Avalyn Pharma Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avalyn Pharma Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avalyn Pharma Inc. (AVLN) by visiting AAII Stock Evaluator.

Relative Price Strength of Avalyn Pharma Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Avalyn Pharma Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Avalyn Pharma Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Avalyn Pharma Inc. Stock Price: Bottom Line

As of September 4, 2026, Avalyn Pharma Inc.’s stock price is $37.390, which is up 5.5% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avalyn Pharma Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.